BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Amylyx at a Crossroads: Can the Company Overcome the Loss of Relyvrio?

  After withdrawing ALS drug Relyvrio from the U.S. and Canadian markets and laying off 70% of its workforce, the Cambridge, Mass.–based biopharma got a much-needed win in Wolfram syndrome.

  April 17, 2024

   · 

  7 min read

   · 

  Heather McKenzie
• 

  Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space

  As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.

  April 17, 2024

   · 

  4 min read

   · 

  Neil Versel
• 

  Biotech Bay

  Canaan Secures More Than $100M in New Biopharma Funding, Adds Former Pfizer Executive

  The Menlo Park, Calif.-based venture capital firm has raised more than $1 billion since last year, with this latest injection of capital going to its biopharma investment funds.

  April 17, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Drug Development

  GSK Touts Late-Stage Antibiotic Win in Gonorrhea, Long-Term Shingrix Vaccine Data

  GSK’s antibiotic eliminated the bacterial cause of gonorrhea in 92.6% of patients in a Phase III study, while its Shingrix vaccine’s efficacy in shingles remained above 70% over 11 years of follow up.

  April 17, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Drug Development

  Amylyx Sheds More Light on Relyvrio’s Late-Stage Trial Failure in ALS

  At this week’s American Academy of Neurology annual meeting, Amylyx provided additional data from its Phase III amyotrophic lateral sclerosis study showing the full extent of Relyvrio’s failure.

  April 17, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Arrowhead’s Plozasiran Poised for Dyslipidemia Market, $700M in Sales by 2032: GlobalData

  On the heels of a Phase IIb win, Arrowhead Pharmaceuticals’ plozasiran could fulfill a critical unmet need in dyslipidemia treatment bringing in $707 million in sales by 2032, according to data analytics firm GlobalData.

  April 17, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Cullinan Targets Autoimmune Market, Nabs $280M in Private Placement

  Cullinan Oncology, now renamed Cullinan Therapeutics, is riding the growing wave of interest in autoimmune disorders by refocusing its bispecific T cell-engager CLN-978 for systemic lupus erythematosus.

  April 17, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study

  With Wednesday’s readout showing symptom improvements in obstructive sleep apnea patients, Eli Lilly is preparing to file for a label expansion for its blockbuster weight-loss drug Zepbound.

  April 17, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop

  Sage Therapeutics announced Wednesday it is scrapping its Parkinson’s disease program after the company’s investigational drug showed no benefit over placebo. Phase II studies of the oral treatment will continue in Huntington’s and Alzheimer’s diseases.

  April 17, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• 

  Career Advice

  How to Deal With Layoff-Related Stress

  Employees worried about layoffs can practice self-care, use employer resources and contact a mental health professional, if needed.

  April 17, 2024

   · 

  4 min read

   · 

  Angela Gabriel